Biotech company Pila Pharma has recently completed a strongly oversubscribed share issue on Nasdaq First North in Stockholm. The company says the raised capital of nearly SEK 30 million ($3 million) will finance the first steps of development of its tablet-based treatment for obesity. Founded by former Novo Nordisk researcher… Read More
Biotech company Pila Pharma has raised 20 million Swedish kronor ($2.08 million) in an almost fully covered capital raise, which includes a stock option for future use. Pila Pharma was founded by Danish researcher Dorte Gram, a former researcher at Novo Nordisk and was the first researcher to screen and… Read More
Dorte Gram, founder of Pila Pharma and a former Novo Nordisk researcher who identified the molecule that became semaglutide, the active ingredient in Ozempic and Wegovy, has raised 10 million SEK ($980,320) for a novel obesity-related study. The money will allow the company to study drug… Read More
